Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Through lifestyle modifications, ADORE will assess the progress of patients based on parameters like reduction in blood sugar levels and weight, among others
Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Acquisition expands Merck’s growing hematology portfolio
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
The symposium was organized to provide an opportunity to highlight the advances of aortic surgery and to discuss the future of aortic aneurysm management.
The certification will open new avenues for our flagship brand “Dr Trust”, enabling them to export these devices to many more countries
Subscribe To Our Newsletter & Stay Updated
